CD38 Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma

被引：0

作者：

Verina, Daniel ^{[1
]}

Fowler, Amanda ^{[2
,3
]}

Louw, Karen ^{[4
]}

Barnes, Yvonne ^{[5
]}

Vickroy, Angela ^{[6
]}

机构：

[1] Mt Sinai Med Ctr, Ctr Excellence Multiple Myeloma, New York, NY 10029 USA

[2] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA

[3] Bristol Myers Squibb, Summit, NJ USA

[4] Mt Sinai Med Ctr, New York, NY USA

[5] Sanofi, Cambridge, MA USA

[6] Wash ington Univ, Barnes Jewish Hosp, Sch Med St Louis, St Louis, MO USA

来源：

JNP- THE JOURNAL FOR NURSE PRACTITIONERS | 2022年 / 18卷 / 07期

关键词：

CD38; daratumumab; isatuximab; monoclonal antibody; multiple myeloma; OPEN-LABEL; DEXAMETHASONE; CARFILZOMIB; DARATUMUMAB; MULTICENTER; ISATUXIMAB; SAR650984; IKEMA;

D O I：

10.1016/j.nurpra.2022.05.001

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Multiple myeloma remains an incurable disease. CD38 is a desirable target for therapeutic antibodies, including isatuximab and daratumumab. Nurse practitioners working in the oncology setting play an essential role in the management and education of patients receiving these therapies. This article provides a practical overview of anti-CD38 antibodies for oncology nurse practitioners, including infusion reaction mitigation, laboratory interpretation, and clinical decision making. (c) 2022 The Author(s). Published by Elsevier Inc.

引用

页码：693 / 698

页数：6

共 34 条

[1]

Alrawashdh N, 2020, 62 ASH ANN M EXPOSIT

[2]

[Anonymous], 2020, FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL

[3]

[Anonymous], 2016, A measure developed by the European Commission to evaluate the regions digital performance

[4] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [J].

Attal, Michel ;

Richardson, Paul G. ;

Rajkumar, S. Vincent ;

San-Miguel, Jesus ;

Beksac, Meral ;

Spicka, Ivan ;

Leleu, Xavier ;

Schjesvold, Fredrik ;

Moreau, Philippe ;

Dimopoulos, Meletios A. ;

Huang, Jeffrey Shang-Yi ;

Minarik, Jiri ;

Cavo, Michele ;

Prince, H. Miles ;

Mace, Sandrine ;

Corzo, Kathryn P. ;

Campana, Frank ;

Le-Guennec, Solenn ;

Dubin, Franck ;

Anderson, Kenneth C. .

LANCET, 2019, 394 (10214) :2096-2107

[5]

Bullock T, INF14761 NAT HLTH SE

[6]

Cabenuva, 2021, Prescribing information

[7]

Cai T, 2013, INT MYEL WORKSH, V13

[8] Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials [J].

Chari, Ajai ;

Stewart, A. Keith ;

Russell, Stuart D. ;

Moreau, Philippe ;

Herrmann, Joerg ;

Banchs, Jose ;

Hajek, Roman ;

Groarke, John ;

Lyon, Alexander R. ;

Batty, George N. ;

Ro, Sunhee ;

Huang, Mei ;

Iskander, Karim S. ;

Lenihan, Daniel .

BLOOD ADVANCES, 2018, 2 (13) :1633-1644

[9]

DARZALEX® (daratumumab), 2020, PRESCRIBING INFORM

[10] SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies [J].

Deckert, Jutta ;

Wetzel, Marie-Cecile ;

Bartle, Laura M. ;

Skaletskaya, Anna ;

Goldmacher, Victor S. ;

Vallee, Francois ;

Zhou-Liu, Qing ;

Ferrari, Paul ;

Pouzieux, Stephanie ;

Lahoute, Charlotte ;

Dumontet, Charles ;

Plesa, Adriana ;

Chiron, Marielle ;

Lejeune, Pascale ;

Chittenden, Thomas ;

Park, Peter U. ;

Blanc, Veronique .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4574-4583

← 1 2 3 4 →